Fulgent Genetics ROE 2015-2025 | FLGT
Current and historical return on equity (ROE) values for Fulgent Genetics (FLGT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Fulgent Genetics ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-03-31 | $-0.04B | $1.12B | -3.72% |
| 2024-12-31 | $-0.04B | $1.13B | -3.81% |
| 2024-09-30 | $-0.17B | $1.14B | -14.59% |
| 2024-06-30 | $-0.16B | $1.13B | -14.02% |
| 2024-03-31 | $-0.17B | $1.13B | -13.79% |
| 2023-12-31 | $-0.17B | $1.13B | -13.56% |
| 2023-09-30 | $-0.06B | $1.26B | -4.98% |
| 2023-06-30 | $-0.05B | $1.26B | -3.78% |
| 2023-03-31 | $-0.03B | $1.27B | -1.95% |
| 2022-12-31 | $0.14B | $1.27B | 11.13% |
| 2022-09-30 | $0.27B | $1.28B | 21.46% |
| 2022-06-30 | $0.39B | $1.31B | 32.52% |
| 2022-03-31 | $0.46B | $1.31B | 41.49% |
| 2021-12-31 | $0.51B | $1.17B | 51.67% |
| 2021-09-30 | $0.57B | $1.04B | 68.35% |
| 2021-06-30 | $0.49B | $0.92B | 79.71% |
| 2021-03-31 | $0.42B | $0.80B | 101.40% |
| 2020-12-31 | $0.21B | $0.57B | 92.64% |
| 2020-09-30 | $0.05B | $0.19B | 43.84% |
| 2020-06-30 | $0.00B | $0.09B | 2.61% |
| 2020-03-31 | $0.00B | $0.08B | -1.48% |
| 2019-12-31 | $0.00B | $0.08B | -1.67% |
| 2019-09-30 | $0.00B | $0.06B | -5.80% |
| 2019-06-30 | $-0.01B | $0.05B | -9.76% |
| 2019-03-31 | $-0.01B | $0.05B | -11.59% |
| 2018-12-31 | $-0.01B | $0.05B | -11.43% |
| 2018-09-30 | $-0.01B | $0.05B | -11.27% |
| 2018-06-30 | $-0.01B | $0.05B | -11.16% |
| 2018-03-31 | $-0.01B | $0.05B | -9.17% |
| 2017-12-31 | $0.00B | $0.05B | -5.45% |
| 2017-09-30 | $0.00B | $0.06B | 0.00% |
| 2017-06-30 | $0.00B | $0.06B | 0.00% |
| 2017-03-31 | $-0.01B | $0.06B | -13.51% |
| 2016-12-31 | $-0.01B | $0.05B | -25.81% |
| 2016-06-30 | $-0.01B | $0.02B | -109.09% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.597B | $0.283B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.950B | 58.46 |
| Tempus AI (TEM) | United States | $11.831B | 0.00 |
| Doximity (DOCS) | United States | $11.347B | 52.53 |
| Hims & Hers Health (HIMS) | United States | $10.359B | 107.63 |
| IRhythm Technologies (IRTC) | United States | $4.875B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.826B | 59.77 |
| Hinge Health (HNGE) | United States | $3.508B | 0.00 |
| Privia Health (PRVA) | United States | $2.682B | 183.33 |
| Enovis (ENOV) | United States | $1.843B | 10.27 |
| Phreesia (PHR) | United States | $1.663B | 0.00 |
| Schrodinger (SDGR) | United States | $1.503B | 0.00 |
| 10x Genomics (TXG) | United States | $1.441B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.420B | 0.00 |
| Azenta (AZTA) | United States | $1.409B | 65.47 |
| Omnicell (OMCL) | United States | $1.351B | 23.83 |
| Evolent Health (EVH) | United States | $1.262B | 107.50 |
| Claritev (CTEV) | United States | $0.703B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.500B | 0.00 |
| Veradigm (MDRX) | United States | $0.487B | 0.00 |
| Standard BioTools (LAB) | United States | $0.482B | 0.00 |
| Talkspace (TALK) | United States | $0.460B | 137.50 |
| Outset Medical (OM) | United States | $0.357B | 0.00 |
| TruBridge (TBRG) | United States | $0.355B | 787.33 |
| Nyxoah SA (NYXH) | Belgium | $0.262B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.261B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.207B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.165B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.133B | 0.00 |
| American Well (AMWL) | United States | $0.118B | 0.00 |
| Pulmonx (LUNG) | United States | $0.104B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.103B | 0.00 |
| CareCloud (CCLD) | United States | $0.096B | 3.68 |
| 111 (YI) | China | $0.064B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.051B | 0.00 |
| HeartBeam (BEAT) | United States | $0.047B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.044B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.039B | 0.00 |
| Zhongchao (ZCMD) | China | $0.031B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.015B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.011B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |